CD30-targeting immunoconjugates and bystander effects

Nature Reviews Clinical Oncology

Volumn 12, Issue 4, 2015, Pages 245-

  Masuda, Shigeo ^a   Miyagawa, Shigeru ^a   Sougawa, Nagako ^a   Sawa, Yoshiki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; CYTOTOXIC AGENT; MONOCLONAL ANTIBODY;

ANTIGEN EXPRESSION; BYSTANDER EFFECT; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; HODGKIN DISEASE; HUMAN; LETTER; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNOTHERAPY; NEOPLASMS; PASSIVE IMMUNIZATION; PROCEDURES; TRENDS;

ANIMALS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOCONJUGATES; IMMUNOTHERAPY; NEOPLASMS;

EID: 84925940025     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.159-c1     Document Type: Letter

References (10)

1. Smaglo, B. G., Aldeghaither, D. & Weiner, L. M. The development of immunoconjugates for targeted cancer therapy. Nat. Rev. Clin. Oncol. 11, 637-648 (2014).
2. Horwitz, S. M. et al. Objective responses in relapsed T-cell lymphomas with single-Agent brentuximab vedotin. Blood 123, 3095-3100 (2014).
3. Okeley, N. M. et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin. Cancer Res. 16, 888-897 (2010).
4. Golfier, S. et al. Anetumab ravtansine: a novel mesothelin-Targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol. Cancer Ther. 13, 1537-1548 (2014).
5. Tai, Y. T. et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 123, 3128-3138 (2014).
6. Tannir, N. M. et al. Novel Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest. New Drugs 32, 1246-1257 (2014).
7. Kularatne, S. A. et al. A CXCR4-Targeted site-specific antibody-drug conjugate. Angew. Chem. Int. Ed. Engl. 53, 11863-11867 (2014).
8. DiPippo, V. A. et al. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts. Prostate 75, 303-313 (2015).
9. Sussman, D. et al. SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol. Cancer Ther. 13, 2991-3000 (2014).
10. Beckwith, K. A. et al. The CD37-Targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia 28, 1501-1510 (2014).